US Patent 10,016,403: Fentanyl Sublingual Formulation Claims, Patent Scope, and Generic Entry Risk
US Patent 10,016,403 protects a sublingual liquid formulation containing fentanyl or specified fentanyl analogs, ethanol, and propylene glycol within defined concentration ranges. The patent is composition-focused. It does not require a particular spray device, dosage volume, indication, preservative, flavoring agent, or manufacturing process. The principal commercial relevance is to sublingual fentanyl products such as Subsys and to abbreviated new drug application, or ANDA, applicants developing equivalent formulations.
What does US Patent 10,016,403 cover?
The patent covers a sublingual formulation comprising three required elements:
| Claim element |
Claim 1 range or limitation |
| Active opioid |
About 0.1% to about 0.9% by weight |
| Ethanol |
About 20% to about 60% by weight |
| Propylene glycol |
About 1% to about 30% by weight |
| Dosage route |
Sublingual |
| Covered active ingredients |
Fentanyl free base, pharmaceutically acceptable fentanyl salt, sufentanil, carfentanil, lofentanil, or alfentanil |
Claim 2 narrows the ethanol limitation to approximately 50% to 60% by weight.
The claims use “comprising,” which is an open-ended transitional term. A formulation can contain additional ingredients and still fall within the claim if it contains the required opioid, ethanol, propylene glycol, and sublingual formulation characteristics.
The patent does not require:
- Fentanyl citrate specifically;
- A spray actuator or metering pump;
- A particular volume per actuation;
- A particular pH;
- Water;
- A preservative;
- A sweetener or flavor;
- A particular therapeutic indication;
- A specific absorption rate;
- A specific manufacturing method.
That breadth creates potential overlap with multiple liquid sublingual delivery systems, provided the formulation satisfies the claimed concentration ranges.
What are the key limitations of claim 1?
Claim 1 has four material limitations.
Sublingual formulation
The product must be formulated for sublingual administration. A conventional oral tablet, transdermal patch, buccal film, nasal spray, injectable product, or oral transmucosal lozenge would not ordinarily satisfy this limitation merely because the same opioid is present.
The sublingual limitation is functional and product-specific. A liquid placed under the tongue is a stronger infringement candidate than a formulation merely capable of being swallowed or absorbed through the oral mucosa.
Active ingredient concentration
The opioid must be present at approximately 0.1% to 0.9% by weight. The claim covers either fentanyl or one of four listed analogs:
- Sufentanil;
- Carfentanil;
- Lofentanil;
- Alfentanil.
The claim also covers fentanyl free base and pharmaceutically acceptable salts. Fentanyl citrate is therefore within the claimed active-ingredient category if its concentration is calculated under the applicable claim-construction method.
The concentration limitation is potentially significant for design-around analysis. A product below approximately 0.1% or above approximately 0.9% could avoid literal infringement, although the effect of “about,” measurement tolerances, prosecution history, and the doctrine of equivalents would remain relevant.
Ethanol concentration
Claim 1 covers approximately 20% to 60% ethanol by weight. Claim 2 is narrower and covers approximately 50% to 60%.
The ethanol limitation is likely to be a central screening parameter for generic products. A formulation containing 45% ethanol could fall within claim 1 but not claim 2. A formulation containing 55% ethanol could fall within both claims.
Propylene glycol concentration
The formulation must contain approximately 1% to 30% propylene glycol by weight. A product containing no propylene glycol would not literally satisfy the claim. The open-ended “comprising” language does not eliminate the requirement for each expressly recited ingredient.
How does claim 2 compare with claim 1?
Claim 2 narrows only the ethanol range.
| Feature |
Claim 1 |
Claim 2 |
| Opioid concentration |
About 0.1% to 0.9% |
Same as claim 1 |
| Ethanol |
About 20% to 60% |
About 50% to 60% |
| Propylene glycol |
About 1% to 30% |
Same as claim 1 |
| Sublingual route |
Required |
Required |
| Additional ingredients permitted |
Yes |
Yes |
A formulation with 20% to less than approximately 50% ethanol may remain exposed to claim 1 while avoiding claim 2. A formulation with 50% to 60% ethanol may face both claims.
What is the patent identity and ownership history?
Public patent records identify US 10,016,403 as an Insys Therapeutics patent directed to sublingual pharmaceutical formulations. The patent issued on July 10, 2018. Its technical subject matter is associated with the formulation platform used for sublingual fentanyl delivery, including the Subsys product family.[1]
| Patent |
Issue date |
Patent holder or recorded assignee |
Technical focus |
| US 10,016,403 |
July 10, 2018 |
Insys Therapeutics, Inc. |
Sublingual opioid formulation containing ethanol and propylene glycol |
Ownership, assignment, and enforcement rights should be checked against the USPTO assignment database because Insys underwent bankruptcy and asset-sale proceedings. Patent ownership at issuance and current enforcement ownership may differ.[3]
When does US Patent 10,016,403 lose exclusivity?
The patent issued in 2018 and has a projected statutory term extending into 2032, subject to the patent’s official term calculation, patent-term adjustment, any terminal disclaimer, and any applicable regulatory extension. The expiration date shown in commercial patent databases should not be treated as controlling over the USPTO patent-term calculation or the FDA Orange Book listing.
The patent’s commercial blocking period can end earlier than the statutory expiration if:
- The patent is invalidated;
- The patent is disclaimed;
- A court finds noninfringement;
- The relevant claims are cancelled or amended;
- A settlement permits earlier generic entry;
- The patent is not listed or is delisted for the relevant product.
The patent does not appear to be a biologic exclusivity patent. Its relevance is to small-molecule fentanyl formulations and ANDA-based generic competition.
What is the FDA and Orange Book status of the patent?
The relevant reference product is Subsys, an FDA-approved sublingual spray containing fentanyl citrate. Subsys was approved under NDA 202880 for breakthrough pain in adults with cancer who are already receiving and tolerant to opioid therapy.[2]
The FDA Orange Book is the controlling source for listed patents, patent-use codes, expiration information, and regulatory exclusivity for an approved drug product. A patent may be technically relevant to a product yet have limited ANDA significance if it is not listed for the reference product or if the listing does not cover the proposed generic use.
| Regulatory issue |
Relevance to US 10,016,403 |
| Active ingredient |
Fentanyl citrate or another covered fentanyl form |
| Dosage form |
Sublingual spray or liquid formulation |
| Regulatory pathway |
NDA reference product; ANDA pathway for generics |
| Biologic pathway |
Not applicable |
| Orange Book importance |
Determines whether the patent can trigger a Paragraph IV certification |
| Use-code risk |
Depends on the scope of any listed method-of-use code |
An Orange Book-listed formulation patent can require an ANDA applicant to submit a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger Hatch-Waxman litigation and a potential 30-month stay of approval, subject to statutory exceptions.[2]
What Paragraph IV challenges and litigation risks exist?
The principal generic challenge would be a Paragraph IV certification directed to the formulation patent or related Subsys patents. The likely legal theories would include:
- Noninfringement based on ethanol concentration;
- Noninfringement based on propylene glycol concentration;
- Noninfringement based on opioid concentration;
- Noninfringement based on a non-sublingual or differently characterized delivery system;
- Invalidity for anticipation;
- Invalidity for obviousness;
- Indefiniteness of “about” or other claim boundaries;
- Lack of written description or enablement;
- Unenforceability based on prosecution conduct, if supported by the record.
The “about” ranges create both infringement and validity issues. A court would likely examine the specification, examples, analytical methods, prosecution history, and industry tolerance conventions before determining how far the claimed ranges extend beyond the stated numerical endpoints.
The open-ended claim language strengthens the patent against formulations that add excipients. It does not eliminate the need to prove every required limitation. A generic product that replaces ethanol with another solvent, removes propylene glycol, or moves outside the opioid concentration range may have a credible noninfringement position.
Publicly available information associates Insys and Subsys with patent enforcement and ANDA disputes involving competing pharmaceutical manufacturers. The existence, status, and settlement terms of any particular case must be evaluated from the relevant federal court docket and current Orange Book records rather than from the patent document alone.
Which related patents may affect generic entry?
A generic applicant should review the entire Subsys patent estate, not US 10,016,403 in isolation. Relevant categories include:
| Patent category |
Potential blocking issue |
| Core formulation patents |
Ethanol, propylene glycol, fentanyl concentration, and sublingual delivery |
| Device patents |
Metered spray, actuator, dose control, and container configuration |
| Method-of-use patents |
Treatment of breakthrough cancer pain or opioid-tolerant patients |
| Manufacturing patents |
Mixing, filling, stability, or content-uniformity processes |
| Formulation-performance patents |
Absorption, onset, dose consistency, and mucosal delivery |
| Continuation patents |
Claims directed to narrower ranges or related compositions |
Continuation and divisional patents can create a layered estate even when the broadest formulation claim expires on the same general timetable. The Orange Book may contain only a subset of the patent family. Unlisted patents can still support infringement litigation, although they generally do not create the same automatic ANDA approval stay.
How strong is the patent estate for a generic entrant?
The strength of US 10,016,403 is moderate to strong against products that closely copy the formulation profile.
Strengths
- The claim covers fentanyl and several potent analogs.
- The claim combines active-ingredient, ethanol, and propylene glycol ranges.
- “Comprising” language permits additional excipients.
- Claim 1 covers a relatively broad ethanol range.
- The sublingual limitation aligns with the commercial dosage form.
- The patent does not depend on a narrow device configuration.
Vulnerabilities
- The numerical ranges may be vulnerable to prior-art formulations.
- “About” can create boundary and indefiniteness disputes.
- A generic manufacturer may design around one required component.
- Fentanyl sublingual formulations may have substantial pre-patent prior art.
- A formulation patent may not block a materially different delivery technology.
- The claim does not cover every fentanyl dosage form or every oral-mucosal product.
The practical risk is highest for a generic liquid sublingual spray using ethanol as the principal solvent and propylene glycol as a co-solvent. Risk declines if the applicant uses a different solvent system, a different route, or a concentration profile outside the claimed ranges.
What generic launch scenarios are most likely?
| Launch scenario |
Patent exposure |
Commercial assessment |
| Copycat liquid spray with 50% to 60% ethanol |
High |
Likely Paragraph IV litigation |
| Liquid spray with 20% to less than 50% ethanol |
Claim 1 exposure remains |
Claim 2 may be avoided, but claim 1 remains relevant |
| Formulation without propylene glycol |
Lower literal infringement risk |
Requires technical validation and regulatory comparability |
| Non-ethanol solvent system |
Lower literal infringement risk |
May face other patents or absorption challenges |
| Sublingual tablet or film |
Lower exposure to this claim |
Could implicate separate dosage-form patents |
| Nasal or buccal product |
Generally outside the claim |
Separate regulatory and patent analysis required |
A first-filer could face the 180-day generic exclusivity framework if it submits a valid Paragraph IV certification and satisfies applicable FDA requirements. The commercial value of that position would depend on whether Subsys remains marketed, whether the reference product has active commercial demand, and whether other patents or regulatory barriers delay approval.
Are biosimilar risks relevant?
No. Fentanyl is a chemically synthesized small molecule, not a biologic subject to the biosimilar pathway. The relevant competitive threat is generic substitution through an ANDA, not biosimilar approval under the Public Health Service Act.
The main technical barriers are formulation equivalence, dose uniformity, spray performance, sublingual absorption, stability, and abuse-deterrence or controlled-substance compliance. FDA approval would also require compliance with fentanyl scheduling and applicable risk-management requirements.
Are licensing deals associated with the patent?
The patent record identifies Insys as the principal originating owner or assignee associated with the formulation technology. Public patent records alone do not establish the existence, scope, or continuing effectiveness of commercial licenses, royalty arrangements, or bankruptcy-related transfers. Any current licensee or enforcement entity must be confirmed through recorded assignments, court filings, transaction documents, or FDA sponsor information.
What is the geographic coverage?
US 10,016,403 provides rights only in the United States. Corresponding international rights depend on the patent family and national-stage filings. A US patent does not block manufacture, sale, or use in Europe, Canada, Japan, or other markets unless corresponding national patents remain in force.
International diligence should examine:
- PCT applications and national-stage entries;
- European Patent Office family members;
- Canadian and Australian equivalents;
- Patent status by jurisdiction;
- Local supplementary protection or patent-term extensions;
- National litigation and settlement terms.
Key Takeaways
- US 10,016,403 claims a sublingual formulation containing approximately 0.1% to 0.9% fentanyl or a listed fentanyl analog, 20% to 60% ethanol, and 1% to 30% propylene glycol.
- Claim 2 narrows ethanol to approximately 50% to 60%.
- The claims are composition claims, not device, manufacturing, or method-of-use claims.
- “Comprising” permits additional formulation ingredients but does not eliminate the required opioid, ethanol, propylene glycol, and sublingual limitations.
- The patent is most relevant to liquid sublingual fentanyl sprays that use ethanol and propylene glycol.
- The patent is expected to remain relevant into approximately 2032, subject to the official USPTO term calculation and any terminal disclaimer.
- Generic challengers would likely use Paragraph IV certifications and focus on noninfringement, anticipation, obviousness, indefiniteness, and written-description arguments.
- Biosimilar competition is irrelevant; the commercial threat is an ANDA generic.
- The complete blocking analysis requires review of the broader Subsys patent estate, Orange Book listings, continuation patents, device patents, method-of-use patents, and any settlement agreements.
FAQs About US Patent 10,016,403
Does US Patent 10,016,403 cover fentanyl citrate?
Yes, if the fentanyl citrate formulation satisfies the claimed concentration ranges and is formulated for sublingual administration. The claim covers fentanyl free base and pharmaceutically acceptable salts.
Does the patent cover a sublingual fentanyl film?
Not necessarily. A film could fall outside the claim depending on its ethanol content, propylene glycol content, opioid concentration, and technical characterization as a sublingual formulation. Separate film or dosage-form patents may apply.
Can a generic avoid the patent by changing the ethanol concentration?
Potentially, but changing ethanol concentration alone may not be sufficient. A formulation below approximately 20% or above approximately 60% may avoid the literal numerical range, while a formulation between approximately 20% and 60% remains exposed to claim 1.
Does the patent cover sufentanil and carfentanil products?
Yes. Claim 1 expressly lists sufentanil and carfentanil, along with lofentanil and alfentanil, as alternative covered active ingredients.
Is US 10,016,403 the only patent relevant to Subsys?
No. Subsys-related exclusivity can involve multiple formulation, device, method-of-use, manufacturing, and continuation patents. Orange Book listings and current USPTO records must be reviewed as a portfolio.
References
- United States Patent and Trademark Office. (2018). US Patent No. 10,016,403, sublingual pharmaceutical formulation.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book; Subsys prescribing information and patent listings.
- United States Patent and Trademark Office. (n.d.). Patent Center and Assignment Search: US Patent No. 10,016,403.
